BML-210 has been shown to inhibit HDAC activity in HeLa nuclear extracts (IC50 = 5-10μM). Furthermore this compound was shown to inhibit growth, stimulate differentiation, and induce apoptosis in several human leukemia cell lines. These effects have been attributed to modulation of histone acetylation levels and subsequent changes in gene expression.
1. Herman, David., et al., 2006. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nature chemical biology. 2(10): 551-8. PMID: 16921367
2. Savickiene, Jurate., et al., 2006. The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines. European journal of pharmacology. 549(1-3): 9-18. PMID: 16978604
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.